Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial

The activity of androgen-deprivation therapy (ADT) in androgen receptor–positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few years. Second-line treatment in castration-resistant patients is still unknown. We investigated the activity of abiraterone acetate as second-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Locati, Laura D., Cavalieri, Stefano, Bergamini, Cristiana, Resteghini, Carlo, Colombo, Elena, Calareso, Giuseppina, Mariani, Luigi, Quattrone, Pasquale, Alfieri, Salvatore, Bossi, Paolo, Platini, Francesca, Capone, Iolanda, Licitra, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677956/
https://www.ncbi.nlm.nih.gov/pubmed/34597119
http://dx.doi.org/10.1200/JCO.21.00468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677956/
https://www.ncbi.nlm.nih.gov/pubmed/34597119
http://dx.doi.org/10.1200/JCO.21.00468

Ejemplares similares